ANIK — Anika Therapeutics Balance Sheet
0.000.00%
- $190.29m
- $132.81m
- $112.82m
- 76
- 45
- 74
- 72
Annual balance sheet for Anika Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 94.4 | 86.3 | 72.9 | 55.6 | 57.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 29.8 | 34.6 | 36 | 23.6 | 23.7 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 169 | 170 | 163 | 114 | 103 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 68.6 | 79 | 75 | 64.7 | 66.3 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 348 | 349 | 271 | 203 | 190 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29.8 | 27.9 | 31.1 | 23.3 | 21.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 60.5 | 63.6 | 58.4 | 48.8 | 46.8 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 287 | 286 | 212 | 154 | 143 |
| Total Liabilities & Shareholders' Equity | 348 | 349 | 271 | 203 | 190 |
| Total Common Shares Outstanding |